CTS Corporation

CTS Corporation (CTS) Market Cap

CTS Corporation has a market capitalization of .

No quote data available.

CEO: Pratik Trivedi

Sector: Technology

Industry: Hardware, Equipment & Parts

IPO Date: 1980-03-17

Website: https://www.ctscorp.com

CTS Corporation (CTS) - Company Information

Market Cap: -|Sector: Technology

Company Profile

CTS Corporation is a global enterprise specializing in the production and distribution of vital electronic components, such as sensors, actuators, and connectivity solutions, with operations spanning North America, Europe, and Asia. Its extensive product line includes specialized sensors and actuators developed for both passenger and commercial vehicles. Additionally, CTS provides advanced connectivity components crucial for telecommunications infrastructure, information technology networks, and other high-speed applications. The company also offers a broad array of switches, temperature sensors, and potentiometers, serving various industries. Furthermore, it fabricates piezoelectric materials and substrates primarily utilized in demanding sectors like medical, industrial, aerospace and defense, and information technology. CTS effectively markets and sells its offerings through a multi-faceted approach, leveraging its internal sales engineers, independent manufacturers' representatives, and an established network of distributors. The company, which traces its origins back to 1896, currently maintains its corporate headquarters in Lisle, Illinois.

Analyst Sentiment

50%
Hold

From 0 Active Polls

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$67.33
▲ +5.00% Upside
Low Target
$48.09
-25% Risk
Median Target
$65.40
2% Mid
High Target
$80.15
25% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CTS CORP (CTS) — Investment Overview

🧩 Business Model Overview

CTS CORP develops and manufactures precision electronic components used inside customer systems, with a strong emphasis on custom and qualified designs. The typical value chain centers on (1) design and engineering collaboration during product qualification, (2) precision manufacturing with tight process controls and quality systems, and (3) continued production tied to ongoing customer programs. Because performance specifications and reliability standards matter at the component level, CTS participates in the customer’s engineering workflow (design-in) rather than selling purely interchangeable off-the-shelf parts.

💰 Revenue Streams & Monetisation Model

Revenue is generated primarily through product sales of precision components (including resistive and interconnect-related offerings), sold into industrial and transportation electronics and other application-driven end markets. Monetisation tends to follow a program-based model: once a design is qualified and incorporated into a customer platform, CTS benefits from repeat orders tied to platform lifecycles. Margin drivers include manufacturing yield and throughput, mix toward higher-spec/custom products, pricing discipline, and the ability to manage material and labor cost volatility. The business model is not subscription-like, but it is characterized by recurring exposure through customer platform replenishment and continued sourcing.

🧠 Competitive Advantages & Market Positioning

CTS’ moat is best described as high switching costs driven by design-in and qualification, reinforced by manufacturing execution and quality credibility. Competitors face friction when attempting to replace qualified components because customers typically require extensive validation, documentation, and reliability testing to change suppliers on mission- or safety-critical electronics. CTS also benefits from process know-how and yield advantages—precision electronics manufacturing is difficult to replicate without proven process capability, and performance requirements create barriers to entry.

  • Switching costs (design-in/qualification): Customer engineering revalidation cycles and risk management make supplier changes slow and costly.
  • Quality/reliability reputation: Components must meet stringent performance criteria, which elevates the importance of demonstrated compliance and process control.
  • Manufacturing know-how: Precision production economics depend on yield, process stability, and scale in specific product categories.

Competitive benchmarking:

  • TE Connectivity and Molex: broad connectivity and components franchises with deep supply chains. Their scale can pressure pricing, but replacing CTS-style qualified precision parts still depends on customer validation and system-level performance.
  • Amphenol: strong in interconnects and engineered solutions; it competes on integration and platform reach. CTS’ advantage is concentrated where precision, reliability, and design-in requirements create less “commoditization.”
  • Industry focus contrast: Larger diversified competitors pursue wide end-market coverage and product breadth, while CTS’ positioning emphasizes precision components where qualification and performance specifications support stickier program relationships.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular increases in electronic content and tighter performance requirements rather than by a single end-market cycle. Key drivers include:

  • Electrification and power management: More advanced power electronics and sensing increase demand for precision passive/precision components and reliable interconnects.
  • Automotive electronics sophistication: Expanded use of driver assistance, vehicle connectivity, and advanced control systems raises requirements for accuracy, stability, and reliability.
  • Industrial automation and instrumentation: Industrial control systems require components that can sustain performance across temperature, vibration, and long operating lifetimes.
  • Medical and other regulated electronics: Reliability and qualification standards support supplier stickiness once designs are validated.
  • Rational replacement and platform refresh cycles: The design-in model can convert engineering wins into multi-year production exposure.

⚠ Risk Factors to Monitor

  • Customer program timing and platform variability: Design wins convert into revenue on qualification and ramp schedules that can shift.
  • Competitive substitution and integration: Customers may pursue integrated solutions or alternative component architectures, which can pressure design-in positions over time.
  • Manufacturing execution and yield: Precision electronics margin depends on stable processes; disruptions can affect output and costs.
  • Concentration and end-market cyclicality: Exposure to transportation and industrial electronics can amplify downturn risk.
  • Supply chain and component availability: Reliance on specialized materials or processing inputs can create cost or availability constraints.

📊 Valuation & Market View

The market typically values CTS as an industrial/technology-enabled manufacturer where cash generation, margin durability, and program longevity are more informative than pure growth. Common valuation approaches in this peer set often rely on EV/EBITDA or P/S supplemented by sensitivity to gross margin, operating leverage, and free-cash-flow conversion. Key valuation drivers include sustaining pricing, mix shift toward higher-spec/custom content, stable yield and utilization, and evidence that engineering wins translate into multi-year production revenue.

🔍 Investment Takeaway

CTS CORP offers a structurally defensible position in precision electronics through design-in switching costs, manufacturing process capability, and quality/reliability credibility. While end markets remain cyclical, the business model’s reliance on qualified programs can support resilience and multi-year visibility when CTS successfully converts engineering participation into long-lived customer sourcing.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"CTS reported Q2’26 revenue of $144.5M and net income of $19.2M (EPS $0.67). Revenue rose +3.6% QoQ (from $139.5M in Q1’26) and +6.5% YoY (vs. $135.5M in Q2’25). Net income increased +11.5% QoQ (from $17.2M) and +3.5% YoY (vs. $18.5M). Profitability strengthened: gross margin expanded to 42.5% (up from 38.5% QoQ and 39.1% YoY), and net margin rose to 13.3% (vs. 12.3% QoQ and 13.7% YoY). Operating income margin improved to 18.5% from 15.1% QoQ, indicating better cost discipline/price mix in the quarter. Cash generation remained solid. Operating cash flow was $33.4M and free cash flow $28.9M, supporting ongoing shareholder returns. The company repurchased shares (-$3.4M) and paid dividends (-$1.1M) in the quarter, with a low payout ratio (~6%). Balance sheet resilience is improving: cash increased to $107.5M, while net debt is slightly negative (-$6.8M). Total assets rose to $791.5M, and equity is very strong at $1.13B (noting prior-quarter equity compression). Total shareholder returns look favorable given strong market momentum: the stock is up +49.9% over 1 year, which should materially boost the total-return assessment."

Revenue Growth

Good

Revenue growth was +3.6% QoQ and +6.5% YoY, showing a steady upward trajectory rather than a deceleration.

Profitability

Strong

Margins improved meaningfully QoQ: gross margin to 42.5% (from 38.5%) and operating margin to 18.5% (from 15.1%), with net margin also rising to 13.3% QoQ.

Cash Flow Quality

Good

Q2’26 operating cash flow was $33.4M and free cash flow $28.9M. Dividends were modest (~$1.1M) with a low payout ratio (~6%), and buybacks continued (-$3.4M).

Leverage & Balance Sheet

Strong

Net debt turned slightly negative (-$6.8M) with cash increasing to $107.5M. Liquidity ratios remain strong (current ratio ~2.61).

Shareholder Returns

Strong

Strong price momentum: +49.9% 1-year change. Capital return was active via share repurchases plus a small dividend yield (~0.06%).

Analyst Sentiment & Valuation

Neutral

No price target was provided. Multiples appear rich (e.g., P/E ~24.3 from provided ratios), which can limit valuation upside despite improving margins.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

CTS delivered strong Q2 2026 profitability expansion alongside diversified growth while transportation stayed pressured. Revenue rose 7% to $145M, with diversified end markets up 15% YoY to 59% of sales, and record margins (41.5% gross margin, +270 bps YoY; 25.4% adjusted EBITDA margin, +~240 bps YoY). Adjusted EPS reached $0.74, but analysts should note ~$0.07 of favorable one-time items from FX and larger customer reimbursements. Book-to-bill stayed healthy for diversified segments (overall 1.1; diversified 1.17; medical 1.21; industrial 1.11), and management highlighted ~$163M transportation award wins, including a ~$100M record North American sensor portfolio award and a new EV customer. Guidance was raised: FY sales $565M–$585M and adjusted EPS $2.55–$2.70. Key risks remain light-vehicle volume softness from tariffs/geopolitics and potential cost pressure from precious metals and Section 301 tariffs, though management expects broad cost-neutrality via customer/supplier collaboration.

AI IconGrowth Catalysts

  • Medical end market revenue $28M (+45% YoY, +14% sequential) driven by sensing/actuation demand in advanced diagnostics and therapeutics
  • Medical book-to-bill 1.21 reinforcing demand sustainability across next-gen diagnostic/therapeutics programs
  • Transportation net awards totaling ~$163M in the quarter, including ~ $100M North American OEM record sensor win and multiple OEM/region wins (NA, Japan, China, Europe)
  • Aerospace & defense improved sequentially (+4% QoQ) as government funding flow begins into key programs; management expects stronger 2H on backlog and bookings
  • Industrial end market momentum: $40M sales (+16% YoY, +6% sequential) and book-to-bill 1.11 with multiple design wins (EMI filters, industrial printing, temperature sensing for heat pumps/refrigeration/pool-spa)

Business Development

  • Industrial: added 2 new customers expanding presence in process instrumentation and next-gen cryogenic nano positioning
  • Aerospace & defense: added 1 new customer focused on defense satellite communication solutions
  • Transportation: new EV customer in North America for seat track position sensor (safety system)
  • Transportation sensor portfolio wins: large sensor award with a North American OEM for integrated wheel speed accelerometer sensing application (~$100M, record for sensors portfolio)
  • Medical: ongoing engagements with leading global medical equipment OEMs for next-generation platform launches across diagnostic imaging, therapeutics, and minimally invasive procedures

AI IconFinancial Highlights

  • Revenue $145M (+7% YoY, +4% sequential); diversified end markets up 15% YoY and 59% of sales (vs 55% YoY prior period)
  • Record adjusted gross margin 41.5% (+270 bps YoY; +200 bps sequential); YoY improvement driven by execution, mix, and ~$1M FX benefit
  • Adjusted EBITDA margin 25.4% (+~240 bps YoY)
  • Adjusted diluted EPS $0.74 (vs $0.57 prior-year); supported by one-time items totaling ~$0.07 favorable EPS impact (foreign currency favorability and larger customer reimbursement)
  • Effective tax rate 21.8% for the quarter (excluding discrete items); FY tax rate guidance 21% to 23% (excluding discrete items)
  • Cash generation strong: operating cash flow $33M; capex $4.6M; free cash flow ~$29M

AI IconCapital Funding

  • Share repurchase: ~64k shares for $3.5M during the quarter
  • Remaining authorization: $78M under current share repurchase program
  • Balance sheet: cash $108M and borrowings $55M at quarter-end

AI IconStrategy & Ops

  • Evolution 2030 focus on profitable growth and operational rigor; diversification acceleration while stabilizing transportation
  • R&D run-rate normalization expected: management expects R&D expenses to get closer to normal as customer reimbursement timing fluctuates
  • Medical capacity expansion already in place; management cited ramp-up in Q2 and expectation of more normalized therapeutics volumes in 2H
  • Cost/price agility emphasized: teams partnering with customers and suppliers to keep tariff and precious metal effects broadly cost-neutral

AI IconMarket Outlook

  • FY 2026 raised guidance: sales $565M to $585M; adjusted diluted EPS $2.55 to $2.70
  • 2H outlook: management expects stronger 2H for aerospace & defense as government funding flow and awards progress
  • Transportation market: global light vehicle production forecasted flat to modestly down; commercial vehicle expected modest growth supported by improving freight fundamentals and prebuy ahead of EPA 2027 emissions regulations
  • Tariffs/geopolitics: management stated no expectation of material impact from recent tariff announcements; will monitor further developments
  • Next update: third quarter 26 results in October

AI IconRisks & Headwinds

  • Transportation light vehicle volumes forecasted flat to modestly down due to tariffs, geopolitics, and consumer demand uncertainties
  • Freight and precious metal/input cost volatility: management monitoring Section 301 tariff changes, precious metal inflation, and input cost pressures
  • R&D timing variability: customer reimbursements can fluctuate, impacting quarter-to-quarter R&D run-rate
  • Transportation book-to-bill not indicative (short-cycle orders), creating timing/visibility limitations versus diversified end markets
  • Competitive and supply-base transition: management noted ongoing work with Cummins’ second source (market share clarity expected by end of year)

Q&A: Analyst Interest

  • R&D normalization & customer reimbursement timing: Management said customer reimbursements fluctuate with program activity levels; R&D should move closer to “normal” going forward, though additional reimbursements may still occur as programs reach higher activity thresholds during the year’s second half.
  • Medical capacity status and volume normalization: Management clarified the capacity expansion referenced previously is already in place, with a Q2 ramp-up. They expect therapeutics volumes to normalize in 2H as ramping converts into steadier demand execution, while therapeutics performance should improve sequentially.
  • Transportation orders/book-to-bill and commercial vehicle dynamics (Cummins): Management explained transportation book-to-bill is typically near 1.0 because orders are short-cycle and thus not predictive. For commercial vehicles, they modeled modest 2H growth from freight rates, pricing, and potential EPA 2027 prebuy; Cummins supply-base transition remains ongoing.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the CTS Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — CTS Corporation (CTS) Financial Profile